Diagnexia Applauds UK Government’s Approval of Digital Pathology for Enhanced Cancer Screening

Digital pathology will enable quicker and more accurate diagnosis by allowing digital review of tissue samples, facilitating remote reporting, and assisting clinicians in obtaining second opinions. The technology involves whole slide imaging, where high-resolution images of entire glass slides can be viewed and stored digitally. The decision to adopt this approach comes after successful trials demonstrating that digital microscopy is as effective as traditional methods. The rollout across the NHS is expected, with NHS England providing guidance on best practices. The UK National Screening Committee, an independent advisory body, plays a crucial role in guiding these screening initiatives. Digital pathology brings several benefits to both care providers and patients alike:

Future of Healthcare: Digital pathology is not just an advancement in technology; it’s a significant step towards the future of healthcare, enabling patient-centric, accessible, and efficient diagnostic services.

Enhanced Access to Pathology Services: Digital pathology provides remote access to expert pathologists, breaking geographical barriers. This facilitates wider reach, especially in areas where access to specialised pathology services is limited.

Alleviation of Screening Backlogs: The integration of digital pathology can significantly reduce the backlog in cancer screening programs. The technology allows for faster processing and analysis of samples, leading to quicker diagnosis and treatment initiation.

Improved Diagnostic Accuracy: Digital pathology employs advanced imaging and AI technologies, enhancing the accuracy of cancer detection. This leads to more precise diagnoses, better-informed treatment decisions, and potentially improves survival rates.

Efficiency and Cost-Effectiveness: The digital transformation of pathology delivers quicker diagnoses with fewer resources than current methods. This translates into cost savings for healthcare systems.

“Diagnexia applauds the UK government’s decision to adopt digital pathology in cancer screening programs, as recommended by the UK National Screening Committee,” says Prof. Runjan Chetty, Chief Medical Officer at Diagnexia.

“This progressive move aligns perfectly with our mission to provide rapid, expert pathology services through our global digital network. We believe that the integration of digital pathology will significantly enhance the efficiency and accuracy of cancer diagnoses, ultimately improving patient outcomes and accomplishing the mission of screening programmes. We are excited to contribute to this transformative phase in healthcare, offering our robust digital solutions to support the NHS in this endeavor.”

As a global digital pathology department providing access to a network of expert subspecialty pathologists, Diagnexia focuses on delivering primary diagnostic or secondary consult reports rapidly, with accelerated turnaround times. Our commitment to reducing diagnostic and screening backlogs and improving patient outcomes resonates with the government’s goal to expedite and improve cancer screening. Diagnexia’s services, registered with the CQC and ISO27001 certified, offer seamless, intuitive reporting and are fully digital, providing unrivaled accessibility for content monitoring and case management from anywhere. Additionally, they are included in The Countess of Chester Hospital National Framework Agreement for Teleradiology, Telepathology, and Telemedicine Services, enabling any NHS hospital to access their services to manage various workloads efficiently. This positions Diagnexia as a pivotal player in supporting the national healthcare system’smove towards advanced digital pathology practices for both diagnostics and now for screening programs.


Katie Higgins
Commercial Marketing Director

Share This Post

Leave a Reply